EUVIMEDEUVIMED entdecken
LeitlinieSystematische Übersicht

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline

Behandlung des multiplen Myeloms: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline

Lisa K Hicks iD, Hans J Messersmith iD, Samer Al Hadidi iD, Rahul Banerjee iD, Benjamin A Derman iD, Shaji Kumar iD, Tanya M Wildes iD, Susan Bal iD, Sita Bhella, Cynthia Chmielewski, Caitlin Costello, Raetasha Dabney und 10 weitere

Journal of Clinical Oncology · 01.04.2026 · 44 (10) · 914-941

DOI: 10.1200/jco-25-02587 ↗

Auf einen Blick

Die Living Guideline wurde aktualisiert. Grundlage sind 161 relevante randomisierte Studien; neue Empfehlungen betreffen unter anderem Daratumumab, Isatuximab und T-Zell-redirecting Therapien.

Fragestellung

Welche Therapieempfehlungen gibt es für das multiple Myelom?

Methode

ASCO und Ontario Health führten ein gemeinsames Expert:innenpanel und eine aktualisierte systematische Literaturübersicht durch.

Ergebnisse

161 relevante randomisierte Studien wurden identifiziert. Aktualisierte Empfehlungen betreffen Therapie bei high-risk smoldering myeloma, Ersttherapie bei transplantierbaren und nicht transplantierbaren Patient:innen sowie Behandlung bei rezidiviertem/refraktärem multiplem Myelom.

Einschränkungen

Lebende Leitlinie; online dynamische Version mit weiteren Aktualisierungen. Die Guideline ist kein definitiver Behandlungsstandard.

Schlussfolgerung der Autor:innen

Die Autor:innen empfehlen aktualisierte Therapieoptionen für mehrere Krankheitsstadien des multiplen Myeloms.

Kernaussagen

  • 161 relevante randomisierte Studien
  • Empfehlungen für Erst-, Erhaltungs- und Rezidivtherapie
  • Lebende Guideline mit achtwöchentlicher Überprüfung

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.04.2026. Verfasst von Lisa K Hicks und 21 weiteren Autor:innen. Beteiligte Einrichtung: St Michael's Hospital & University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 122 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To provide updated guidance regarding the therapy for multiple myeloma. METHODS ASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature. RESULTS The updated review identified a total of 161 relevant randomized trials. UPDATED RECOMMENDATIONS Daratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles. Additional information is available at www.asco.org/hematologic-malignancies-guidelines .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHumansOntarioRandomized Controlled Trials as Topic

Autor:innen und Institutionen

  • St Michael's Hospital & University of Toronto, Toronto, ON, Canada.
  • American Society of Clinical Oncology (ASCO), Alexandria, VA.
  • University of Texas Southwestern Medical Center, Dallas, TX.
  • Fred Hutchinson Cancer Center, Seattle, WA.
  • University of Chicago, Chicago, IL.
  • Mayo Clinic, Rochester, MN.

ORCID-Profile: Lisa K Hicks, Hans J Messersmith, Samer Al Hadidi, Rahul Banerjee, Benjamin A Derman, Shaji Kumar, Tanya M Wildes, Susan Bal, Monique Hartley-Brown, Brea Lipe, Arleigh McCurdy, Hira Mian, Eloisa Riva

Zitieren

APA

Hicks, L. K., Messersmith, H. J., Al Hadidi, S., Banerjee, R., Derman, B. A., Kumar, S., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., Costello, C., Dabney, R., Hartley-Brown, M., Langerak, A., Lipe, B., Martin, T., McCurdy, A., Mian, H., Riva, E., …, & Mikhael, J. (2026). Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline. Journal of Clinical Oncology, 44(10), 914-941. https://doi.org/10.1200/jco-25-02587

Vancouver

Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, et al. Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline. Journal of Clinical Oncology. 2026;44(10):914-941. doi:10.1200/jco-25-02587

BibTeX
@article{Hicks2026,
  author = {Hicks, Lisa K and Messersmith, Hans J and Al Hadidi, Samer and Banerjee, Rahul and Derman, Benjamin A and Kumar, Shaji and Wildes, Tanya M and Bal, Susan and Bhella, Sita and Chmielewski, Cynthia and Costello, Caitlin and Dabney, Raetasha and Hartley-Brown, Monique and Langerak, Alan and Lipe, Brea and Martin, Thomas and McCurdy, Arleigh and Mian, Hira and Riva, Eloisa and Seth, Rahul and Subramanian, Latha and Mikhael, Joseph},
  title = {Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {10},
  pages = {914--941},
  doi = {10.1200/jco-25-02587}
}
Kostenlos starten →